To investigate whether ZC-22 retained the CDK4/6 inhibitory activity of Abemaciclib, we determined the Rb phosphorylation and cell-cycle distribution in breast and ovarian cancer cells treated with Abemaciclib (LY-2) or ZC-22. This evidence concerns the gene RB1 and ovarian carcinoma.